Since 2014, Pharmassist has been focused on the development and commercialization of CE-IVD molecular diagnostic products in oncology, building its core assets through a strong intellectual property portfolio and proprietary technologies.
To date, Pharmassist has secured multiple granted patents through PCT and national applications across major international markets, including Europe, the United States, Japan, China, Canada, Hong Kong, India and Israel, supporting the global development of the Oncolipsy product line.
The company operates privately owned manufacturing facilities fully compliant with international quality standards and certified according to ISO 9001, ISO 13485 requirements and Manufacturing License for IVD medical devices.
Our vision is to advance precision oncology through innovative and clinically actionable molecular diagnostic solutions that support timely and personalized treatment decisions.
Through minimally invasive liquid biopsy technologies and targeted biomarker detection approaches, we aim to empower healthcare professionals with reliable diagnostic insights while improving patient management and clinical outcomes.
At Pharmassist, we believe that every patient deserves access to precise, timely and personalized cancer care, and we are committed to contributing to the future of oncology diagnostics through continuous innovation.
